Trade Summary

5 days ago, Schneider Eugene, serving as EVP, Chf Clinical Develop Ofcr at Ionis Pharmaceuticals Inc (IONS), sold 5,812 shares at $70.97 per share, for a total transaction value of $412,486.00. Following this transaction, Schneider Eugene now holds 63,890 shares of IONS.

This sale represents a 8.00% decrease in Schneider Eugene's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, March 19, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 23, 2026, 4 days after the trade was made.

Ionis Pharmaceuticals Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.